Now approved for use in 170 VA hospitals nationwide, advancing a new standard in infection prevention
PHILADELPHIA, PA – November 5th 2025– With November being C. diff (Clostridioides difficile) Awareness Month, Philadelphia-based biotech LIV Process is drawing national attention to one of the most stubborn and costly healthcare-associated infections—and the urgent need for new approaches in infection prevention.
LIV Process, a healthcare innovation company specializing in microbial visualization technology, today announced that it has received contract approval from the Veterans Health Administration (VHA) for deployment across its network of 170 hospitals nationwide. This authorization marks a major milestone in the company’s mission to help healthcare providers identify and eliminate harmful pathogens before they endanger patients.
There are several disinfectants that kill bacteria, but until now there has been no way to verify C. diff is no longer present on high-touch surfaces in hospitals, nursing homes, and long-term care facilities. LIV Process’s patented solution binds to viable spores and illuminates them under a specific wavelength of light, revealing contamination invisible to the naked eye. This patented, water-based, non-toxic solution allows hospitals to visually confirm cleaning effectiveness, provide real-time feedback to environmental services (EVS) staff, and strengthen infection-prevention protocols across clinical settings.
“C. diff spores are notoriously difficult to kill and can persist for months even after terminal cleaning,” said Michael McIntyre, Founder and CEO of LIV Process. “Our mission is to save lives by making the invisible visible. With approval from the Veterans Health Administration, LIV Process can now empower hospitals across the VA network to detect pathogens before they cause harm and help set a new national standard in infection prevention.”
According to the CDC, C. diff remains one of the leading causes of healthcare-associated infections (HAIs) in the U.S., infecting nearly 500,000 patients each year and contributing to over 29,000 deaths annually. Among adults aged 65 and older, one in eleven who develop a C. diff infection die within a month. Despite decades of prevention strategies such as hand hygiene and antimicrobial stewardship, infection rates remain high.
A 2019 U.S.-wide study published in EClinicalMedicine concluded that hospital policies alone are insufficient and called for new, multifaceted approaches that extend beyond standard cleaning. LIV Process directly addresses that gap by allowing hospitals to see where contamination remains and continuously improve infection prevention protocols.
In addition to its new VHA approval, LIV Process is collaborating with leading healthcare systems—including University of Virginia Health, University Health San Antonio, University of Texas Southwestern, University of Massachusetts, Duke University Medical Center, Cleveland VA, Houston Methodist, and Baptist Health—to validate and expand adoption of its groundbreaking visualization technology. The company is also partnering with the Peggy Lillis Foundation (https://cdiff.org/) to advance a nationwide C. diff awareness movement, focused on educating the public, empowering advocates, and shaping policy to reduce infections on both a national and global scale.
While hospitals remain the initial focus, LIV Process is exploring future applications for its technology in home healthcare, long-term care facilities, food safety, and public venues in any environment where surface contamination poses a health risk.